Benitec Biopharma price target raised to $8 from $6 at JMP Securities

JMP Securities raised the firm’s price target on Benitec Biopharma to $8 from $6 and keeps an Outperform rating on the shares. A recent sentiment shift in smid-cap biotech land, primarily driven by continued M&A, improves the outlook, the analyst tells investors in a research note. Benitec’s first-in-human BB-301 data could validate its unique silence and replace strategy and generate significant upside in 2024, the firm adds.